Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
The combination also improves HbA1c, fasting glucose, and preserves lean muscle mass better than tirzepatide monotherapy
Woenckhaus M, Klein-Hitpass L, Grepmeier U, Merk J, Pfeifer M, Wild P, Bettstetter M, Wuensch P, Blaszyk H, Hartmann A, et al
Stop using Tirzepatide and get medical help right away if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue or throat, problems breathing or swallowing, severe rash or itching, fainting or feeling dizzy, and very rapid heartbeat
HFpEF with obesity
Beyond the four molecules above, dual-agonists targeting GLP-1 plus other targets (amylin, FGF21, leptin, glucagon variants) are in earlier clinical and pre-clinical development
Specific metabolic changes observed during GLP-1 treatment include: Improved insulin sensitivity , allowing cells to use glucose more efficiently Reduced hepatic glucose production , contributing to better glycaemic control Changes in body composition , with loss of both fat mass and some lean tissue Alterations in lipid metabolism , often resulting in improved cholesterol profiles Body composition studies suggest that lean tissue loss typically accounts for approximately 20-30% of total weight lost during GLP-1 therapy, though this varies considerably between individuals and depends on concurrent physical activity and protein intake
